MERZ-THERAPEUTICS
Today, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, has been granted the use of XEOMIN® for the symptomatic treatment in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg of chronic sialorrhea due to neurological / neurodevelopmental disorders on EU level.1 The national approvals of the country authorities involved will follow in the next weeks. The U.S. Food and Drug Administration granted approval in December 2020, and the Russian Federal Service for Surveillance in Healthcare in spring 2021.
Stefan Brinkmann, CEO Merz Therapeutics: “At Merz Therapeutics, we do everything to bring better outcomes to more patients. As XEOMIN® is already approved for the treatment of adult sialorrhea, we can now offer life-long treatment with our botulinum toxin A, staying a trusted partner for sialorrhea patients as well as their relatives and physicians for a lifetime.”
Dr. Marcus Gollub, President, Head of Region Europe complements: “Pediatric sialorrhea is a serious condition that can significantly impact not only the medical condition but also the quality of life of the children and their families. I am happy that with this new indication we are able to take care of the needs of those children suffering from drooling and contribute to a better life for them and their families.”
Sialorrhea, also known as drooling, is a symptom that occurs when excessive saliva accumulates in the mouth. It is a chronic impairment often seen in children with neurological disorders (e.g. cerebral palsy or traumatic brain injury) and/or intellectual disability or neurodegenerative diseases.
The approval by European authorities for the use of XEOMIN® for pediatric patients suffering from chronic sialorrhea, was achieved due to the convincing results of the SIPEXI study (Si alorrhea Pe diatric X eomin I nvestigation). It was a prospective, randomized, double-blind, placebo-controlled, multicenter phase III study with an extension phase evaluating the safety and efficacy of XEOMIN® in 255 children and adolescents aged 2 – 17 years up to 64 weeks. The study recently got published in Neurology, the premier peer-reviewed journal for clinical neurology research.2
XEOMIN® is being distributed by Merz Pharmaceuticals GmbH in more than 70 countries to treat patients with upper and lower limb spasticity, cervical dystonia, blepharospasm or hypersalivation. Merz uses state-of-the-art technology in its dedicated facility in Dessau, Germany, meeting the highest international standards for biologic manufacturing. The highly purified 150kDa neurotoxin is the only active ingredient in XEOMIN® . It is produced by removing complexing proteins from botulinum toxin type A, using XTRACT® purification technology developed by Merz Pharma GmbH & Co. KGaA.
XEOMIN® is the registered trademark of Merz Pharma GmbH & Co. KGaA.
1
European SmPC (Summary of product characteristics), 2021-08-31
2
Berweck et al. Neurology. 2021 Aug 2:10.1212/WNL.0000000000012573. doi: 10.1212/WNL.0000000000012573.
About Merz Therapeutics
Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that meet patient and customer needs.
Please visit www.merz.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210831005540/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cencora Enhances Global Pharmaceutical Logistics Services, Cold Chain Capabilities3.12.2025 13:30:00 CET | Press release
Expanded capabilities in Europe and the United States enable company to deliver enhanced third-party logistics support to pharmaceutical companies Cencora, a global pharmaceutical solutions company, today announced investments to enhance its third-party logistics (3PL) capabilities in the United States and Europe, expanding its global network and strengthening the specialty logistics services it can deliver to pharmaceutical companies worldwide. As more specialty pharmaceuticals reach the market and the demand for comprehensive drug supply management continues to increase, Cencora is enhancing its global 3PL services offering by: Increasing capabilities in key markets in Europe: Cencora is expanding its pan-European logistics capabilities through the addition of NextPharma Logistics, a healthcare logistics provider that delivers services across Germany, Austria and Switzerland. Cencora also will open a 3PL facility in Italy in 2026, building on recent investments to expand storage capa
Philip Morris International Expands its Partnership with Scuderia Ferrari HP, Launching a Bold New Chapter in Their Long-Standing Relationship3.12.2025 12:00:00 CET | Press release
ZYN Branding to be present in selected races, starting with the Formula 1 Etihad Airways Abu Dhabi Grand Prix 2025 Philip Morris International Inc. (NYSE: PM) today announced an expanded partnership with Scuderia Ferrari HP and with Ferrari Challenge Trofeo Pirelli—the single-marque motorsport championship created in 1993—for the 2026 season and beyond. This next chapter introduces one major development: the ZYN brand of nicotine pouches—the number one nicotine pouch brand globally1—will feature on Scuderia Ferrari HP Formula 1 liveries at select races throughout the seasons. This bold new chapter reinforces a spirit of relentless innovation and unforgettable experiences that has defined the partnership for more than five decades—making it one of the strongest in sports history. To mark this moment, ZYN branding will first feature on the Scuderia Ferrari HP car livery during the Abu Dhabi Grand Prix 2025 scheduled for December 7. “PMI shares with Scuderia Ferrari HP the pursuit to inno
LumRisk Announces Strategic Reset and USD 5 Million Capital Commitment to Accelerate Its Transformation Toward an AI-Driven QIS and Multi-Asset Platform3.12.2025 11:30:00 CET | Press release
LumRisk today announced a major milestone in its evolution, with the approval and implementation of a comprehensive corporate reset. This includes the restructuring of legacy obligations and the reinforcement of the company’s balance sheet. These measures establish a strong foundation for a new phase of accelerated global growth across LumRisk’s core domains: Quantitative Investment Strategies (QIS) and Multi-Asset Analytics. As part of this strategic renewal, LumRisk has secured shareholder approval for a USD 5 million equity commitment, subject to customary conditions. This capital is intended to be deployed to scale the company’s next-generation platform, reinforce its data and technology capabilities, and deepen its offering across the global QIS ecosystem. In parallel, LumRisk is implementing a new management-led corporate structure, under which the leadership team will assume full operational control and a majority equity position upon finalisation of the process. This realignmen
Reply Awarded a 2025 AWS Partner of the Year Award3.12.2025 10:00:00 CET | Press release
Reply recognized as winner for EMEA Partner of the Year, Industry Energy & Utilities, one of many AWS Partners around the globe that help their customers drive innovation Reply [EXM, STAR: REY] is pleased to announce it is a recipient of a 2025 Geography and Global AWS Partner Award, recognizing leaders around the globe that are playing key roles in helping their customers drive innovation and build solutions on Amazon Web Services (AWS). Reply has been named the winner of the EMEA Partner of the Year – Industry Energy & Utilities award, which recognizes top AWS Partners with the AWS Energy Competency, which help customers build and implement advanced solutions powered by AWS across the industry value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251203089630/en/ Through its specialized companies — including Airwalk Reply, Comsysto Reply, Data Reply, Sense Reply, and Storm Reply — Reply leverages AWS capabilities to
FiRa Consortium Unveils FiRa Core 4.0 Specifications and Certification Program3.12.2025 10:00:00 CET | Press release
Featuring UL-TDoA, Aliro UWB updates, and expanded certification The FiRa® Consortium announces the release of its Core 4.0 Specifications and Certification Program, notable milestones in ultra-wideband (UWB) technology development. These updates complete the work of IEEE 802.15.4-2024 features to fulfill FiRa-defined use cases. They also enhance FiRa’s capabilities, enabling seamless interoperability and unlocking new possibilities for precise and secure ranging and positioning in diverse applications. Features of the FiRa Core 4.0 Specifications and Certification Program The FiRa Core 4.0 Specifications include updates that support expanded functionality and continued ecosystem growth. UL-TDoA – This feature enables the tracking of assets (UL-TDoA tags) by an infrastructure made of UL-TDoA anchors. The design ensures interoperability between the tags and the infrastructure, which optimizes tag simplicity and power consumption. The flexible design allows easy and customized deployment
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom